BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, May 5, 2026
Home » Authors » John Fox

John Fox

Articles

ARTICLES

ERB found to play key role in neural stem cell differentiation

Nov. 22, 2017
By John Fox
Estrogen receptor beta (ER-beta) is an important factor that should be considered in the design of new stem cell-based regenerative therapies for neurodegenerative conditions, a new Swedish-American collaborative study has concluded.
Read More

IL-11 identified as therapeutic target for cardiovascular fibrosis

Nov. 20, 2017
By John Fox

IL-11 identified as therapeutic target for cardiovascular fibrosis

Nov. 17, 2017
By John Fox
Researchers at Duke-National University of Singapore (Duke-NUS) Medical School have discovered for the first time that interleukin-11 (IL-11) may be an important therapeutic target for cardiovascular (CV) fibrotic diseases, including heart and renal failure, they reported in the Nov. 13, 2017, edition of Nature.
Read More

Axon assemblies pave way for drug discovery

Nov. 16, 2017
By John Fox

Axon assemblies pave way for drug discovery

Nov. 15, 2017
By John Fox
The creation of a new microdevice that allows generation of three-dimensional (3-D) axonal structures from human stem cell-derived neurons should facilitate future studies on axon development and allow drug screening for diseases including amyotrophic lateral sclerosis (ALS), a new study has found.
Read More

Axon assemblies pave way for drug discovery

Nov. 13, 2017
By John Fox
The creation of a new microdevice that allows generation of three-dimensional (3-D) axonal structures from human stem cell-derived neurons should facilitate future studies on axon development and allow drug screening for diseases including amyotrophic lateral sclerosis (ALS), a new study has found.
Read More

Molecular map may hold key to new cancer treatments

Nov. 9, 2017
By John Fox

Molecular map may hold key to new cancer treatments

Nov. 8, 2017
By John Fox
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Read More

Molecular map may hold key to new cancer treatments

Nov. 7, 2017
By John Fox
The first 3-D map has been produced of the scaffold of a molecule called SgK223, which is now known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.
Read More

Erythropoietin said to induce antiangiogenic drug resistance

Nov. 3, 2017
By John Fox
View All Articles by John Fox

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 4, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Auvelity

    Axsome’s Auvelity cleared for large Alzheimer’s agitation market

    BioWorld
    Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
  • Pancreas

    Sonire starts US study of cancer HIFU after $18M series A

    BioWorld
    Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
  • Xray showing lung cancer on tablet

    How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III

    BioWorld
    Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing